Stem cells: A model for screening, discovery and development of drugs

Stem Cells and Cloning: Advances and Applications

Volumn 4, Issue 1, 2011, Pages 51-59

  Kitambi, Satish Srinivas ^a   Chandrasekar, Gayathri ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer stem cells; Drug development; High throughput screening; Screening models; Stem cells; Therapeutics

Indexed keywords

CANCER STEM CELL; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL RENEWAL; CELL SCREENING; DRUG RESEARCH; DRUG SCREENING; EMBRYONIC STEM CELL; HUMAN; IN VITRO STUDY; MOLECULAR DYNAMICS; MOLECULAR IMAGING; MOLECULAR MODEL; MULTIPOTENT STEM CELL; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; STEM CELL RESEARCH; TARGET CELL;

ANIMALIA;

EID: 84864293546     PISSN: None     EISSN: 11786957     Source Type: Journal    
DOI: 10.2147/SCCAA.S16417     Document Type: Review

References (101)

1. Brittan M, Wright NA. Gastrointestinal stem cells. J Pathol. 2002;197(4): 492-509.
2. Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol. 2006;169(2):338-346.
3. Bussolati B, Bruno S, Grange C, et al. Isolation of renal progenitor cells from adult human kidney. Am J Pathol. 2005;166(2):545-555.
4. Dhawan J, Rando TA. Stem cells in postnatal myogenesis: molecular mechanisms of satellite cell quiescence, activation and replenishment. Trends Cell Biol. 2005;15(12):666-673.
5. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005;121(6): 823-835.
6. Peault B, Rudnicki M, Torrente Y, et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther. 2007;15(5):867-877.
7. Schaffler A, Buchler C. Concise review: adipose tissue-derived stromal cells - basic and clinical implications for novel cell-based therapies. Stem Cells. 2007;25(4):818-827.
8. Van Vliet P, Sluijter JP, Doevendans PA, Goumans MJ. Isolation and expansion of resident cardiac progenitor cells. Expert Rev Cardiovasc Ther. 2007;5(1):33-43.
9. Burns CE, Zon LI. Portrait of a stem cell. Dev Cell. 2002;3(5):612-613.
10. Behfar A, Perez-Terzic C, Faustino RS, et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med. 2007;204(2):405-420.
11. Bujan J, Pascual G, Corrales C, Gomez-Gil V, Garcia-Honduvilla N, Bellon JM. Muscle-derived stem cells used to treat skin defects prevent wound contraction and expedite reepithelialization. Wound Repair Regen. 2006;14(2):216-223.
12. Chang YC, Shyu WC, Lin SZ, Li H. Regenerative therapy for stroke. Cell Transplant. 2007;16(2):171-181.
13. Gangaram-Panday ST, Faas MM, de Vos P. Towards stem-cell therapy in the endocrine pancreas. Trends Mol Med. 2007;13(4):164-173.
14. Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm Res. 2007;24(5):819-841.
15. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res. 2007;100(9):1249-1260.
16. Goldman SA. Disease targets and strategies for the therapeutic modulation of endogenous neural stem and progenitor cells. Clin Pharmacol Ther. 2007;82(4):453-460.
17. Ma Y, Xu Y, Xiao Z, et al. Reconstruction of chemically burned rat corneal surface by bone marrow-derived human mesenchymal stem cells. Stem Cells. 2006;24(2):315-321.
18. McMullen NM, Pasumarthi KB. Donor cell transplantation for myocardial disease: does it complement current pharmacological therapies? Can J Physiol Pharmacol. 2007;85(1):1-15.
19. Mimeault M, Batra SK. Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells. 2006;24(11):2319-2345.
20. Oh SH, Witek RP, Bae SH, et al. Bone marrow-derived hepatic oval cells differentiate into hepatocytes in 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. Gastroenterology. 2007; 132(3):1077-1087.
21. Small TN, Young JW, Castro-Malaspina H, et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant. 2007;13(2):235-244.
22. Trzaska KA, Rameshwar P. Current advances in the treatment of Parkinson's disease with stem cells. Curr Neurovasc Res. 2007;4(2): 99-109.
23. Abdallah BM, Kassem M. The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: current status and future perspectives. J Cell Physiol. 2009;218(1):9-12.
24. Barbaric I, Gokhale PJ, Andrews PW. High-content screening of small compounds on human embryonic stem cells. Biochem Soc Trans. 2010; 38(4):1046-1050.
25. Laustriat D, Gide J, Peschanski M. Human pluripotent stem cells in drug discovery and predictive toxicology. Biochem Soc Trans. 2010;38(4): 1051-1057.
26. Yamanaka S. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif. 2008;41 Suppl 1:51-56.
27. Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. Nature. 2010;465(7299):704-712.
28. Fierabracci A. Recent patents for isolating, delivering and tracking adult stem cells in regenerative medicine. Recent Pat Drug Deliv Formul. 2010;4(2):105-113.
29. Maltman DJ, Przyborski SA. Developments in three-dimensional cell culture technology aimed at improving the accuracy of in vitro analyses. Biochem Soc Trans. 2010;38(4):1072-1075.
30. Danovi D, Falk A, Humphreys P, et al. Imaging-based chemical screens using normal and glioma-derived neural stem cells. Biochem Soc Trans. 2010;38(4):1067-1071.
31. Kobel S, Lutolf M. High-throughput methods to define complex stem cell niches. Biotechniques. 2010;48(4):ix-xxii.
32. Bahadduri PM, Polli JE, Swaan PW, Ekins S. Targeting drug transporters - combining in silico and in vitro approaches to predict in vivo. Methods Mol Biol. 2010;637:65-103.
33. Ishizaki T. Strategic proposals to avoid drug interactions during drug development: a lesson from a terfenadine-related drug interaction. J Toxicol Sci. 1996;21(5):301-303.
34. Roden DM. Torsade de pointes. Clin Cardiol. 1993;16(9):683-686.
35. Bradlaw JA. Evaluation of drug and chemical toxicity with cell culture systems. Fundam Appl Toxicol. 1986;6(4):598-606.
36. Gomez-Lechon MJ, Lahoz A, Gombau L, Castell JV, Donato MT. In vitro evaluation of potential hepatotoxicity induced by drugs. Curr Pharm Des. 2010;16(17):1963-1977.
37. Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ. Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab. 2008;9(1):1-11.
38. Pol A, Bergers M, van Ruissen F, Pfundt R, Schalkwijk J. A simple technique for high-throughput screening of drugs that modulate normal and psoriasis-like differentiation in cultured human keratinocytes. Skin Pharmacol Appl Skin Physiol. 2002;15(4):252-261.
39. Tremblay PL, Berthod F, Germain L, Auger FA. In vitro evaluation of the angiostatic potential of drugs using an endothelialized tissue-engineered connective tissue. J Pharmacol Exp Ther. 2005;315(2):510-516.
40. Nirmalanandhan VS, Sittampalam GS. Stem cells in drug discovery, tissue engineering, and regenerative medicine: emerging opportunities and challenges. J Biomol Screen. 2009;14(7):755-768.
41. Augello A, Kurth TB, De Bari C. Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches. Eur Cell Mater. 2010;20:121-133.
42. Keung AJ, Healy KE, Kumar S, Schaffer DV. Biophysics and dynamics of natural and engineered stem cell microenvironments. Wiley Interdiscip Rev Syst Biol Med. 2010;2(1):49-64.
43. Gardner RL. Stem cells and regenerative medicine: principles, prospects and problems. C R Biol. 2007;330(6-7):465-473.
44. Greenberger JS, Goff JP, Bush J, et al. Expansion of hematopoietic stem cells in vitro as a model system for human tissue engineering. Orthop Clin North Am. 2000;31(3):499-510.
45. Anzalone R, Lo Iacono M, Corrao S, et al. New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cells Dev. 2010;19(4):423-438.
46. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004;36(4): 568-584.
47. Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol. 2006(174):249-282.
48. Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med (Maywood). 2001;226(6):507-520.
49. Tocci A, Forte L. Mesenchymal stem cell: use and perspectives. Hematol J. 2003;4(2):92-96.
50. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene. 2004;23(43):7267-7273.
51. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111.
52. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004; 14(1):43-47.
53. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737.
54. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med. 2008; 12(2):374-390.
55. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267-284.
56. Rice KN, Jamieson CH. Molecular pathways to CML stem cells. Int J Hematol. 2010;91(5):748-752.
57. Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol Oncol Clin North Am. 2010;24(1):35-63.
58. Yamazaki H, Nishida H, Iwata S, Dang NH, Morimoto C. CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells. Biochem Biophys Res Commun. 2009; 383(2):172-177.
59. Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Br J Cancer. 2010;103(4):439-445.
60. Brown P, Smith FO. Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date. Paediatr Drugs. 2008;10(2): 85-92.
61. Martinelli G, Iacobucci I, Papayannidis C, Soverini S. New targets for Ph+ leukaemia therapy. Best Pract Res Clin Haematol. 2009;22(3): 445-454.
62. Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009;15(6):501-513.
63. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105(11):4163-4169.
64. Amore BM, Gibbs JP, Emery MG. Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings. Comb Chem High Throughput Screen. 2010;13(2):207-218.
65. LeBaron MJ, Rasoulpour RJ, Klapacz J, Ellis-Hutchings RG, Hollnagel HM, Gollapudi BB. Epigenetics and chemical safety assessment. Mutat Res. 2010;705(2):83-95.
66. Shah A, Garzon-Muvdi T, Mahajan R, Duenas VJ, Quinones-Hinojosa A. Animal models of neurological disease. Adv Exp Med Biol. 2010;671: 23-40.
67. Guguen-Guillouzo C, Corlu A, Guillouzo A. Stem cell-derived hepatocytes and their use in toxicology. Toxicology. 2010;270(1):3-9.
68. Das T, Cagan R. Drosophila as a novel therapeutic discovery tool for thyroid cancer. Thyroid. 2010;20(7):689-695.
69. Giacomotto J, Segalat L. High-throughput screening and small animal models, where are we? Br J Pharmacol. 2010;160(2):204-216.
70. Gosai SJ, Kwak JH, Luke CJ, et al. Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin alpha1-antitrypsin Z. PloS One. 2010;5(11):e15460.
71. Smith KA, Rex EB, Komuniecki RW. Are Caenorhabditis elegans receptors useful targets for drug discovery: pharmacological comparison of tyramine receptors with high identity from C. elegans (TYRA-2) and Brugia malayi (Bm4). Mol Biochem Parasitol. 2007;154(1):52-61.
72. Link EM, Hardiman G, Sluder AE, Johnson CD, Liu LX. Therapeutic target discovery using Caenorhabditis elegans. Pharmacogenomics. 2000;1(2):203-217.
73. Pagliarini RA, Xu T. A genetic screen in Drosophila for metastatic behavior. Science. 2003;302(5648):1227-1231.
74. Plowman GD, Sudarsanam S, Bingham J, Whyte D, Hunter T. The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms. Proc Natl Acad Sci U S A.1999;96(24): 13603-13610.
75. Tickoo S, Russell S. Drosophila melanogaster as a model system for drug discovery and pathway screening. Curr Opin Pharmacol. 2002; 2(5):555-560.
76. Shulman JM, Shulman LM, Weiner WJ, Feany MB. From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease. Curr Opin Neurol. 2003;16(4):443-449.
77. Bates GP, Hockly E. Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? Curr Opin Neurol. 2003;16(4): 465-470.
78. Gunawardena S, Her LS, Brusch RG, et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron. 2003;40(1):25-40.
79. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev. 2003;2(1):38-51.
80. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol. 2003;3(5):563-570.
81. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature. 2001;414(6859):98-104.
82. Pieper AA, Xie S, Capota E, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010;142(1):39-51.
83. Furutani-Seiki M, Wittbrodt J. Medaka and zebrafish, an evolutionary twin study. Mech Dev. 2004;121(7-8):629-637.
84. Mitani H, Kamei Y, Fukamachi S, et al. The medaka genome: why we need multiple fish models in vertebrate functional genomics. Genome Dyn. 2006;2:165-182.
85. Scholz S, Mayer I. Molecular biomarkers of endocrine disruption in small model fish. Mol Cell Endocrinol. 2008;293(1-2):57-70.
86. Kitambi SS, McCulloch KJ, Peterson RT, Malicki JJ. Small molecule screen for compounds that affect vascular development in the zebrafish retina. Mech Dev. 2009;126(5-6):464-477.
87. Sukardi H, Ung CY, Gong Z, Lam SH. Incorporating zebrafish omics into chemical biology and toxicology. Zebrafish. 2010;7(1):41-52.
88. Currie PD, Schilling TF, Ingham PW. Small-scale marker-based screening for mutations in zebrafish development. Methods Mol Biol. 2008;461:493-512.
89. Haffter P, Nusslein-Volhard C. Large scale genetics in a small vertebrate, the zebrafish. Int J Dev Biol. 1996;40(1):221-227.
90. Biechele TL, Camp ND, Fass DM, et al. Chemical-genetic screen identifies riluzole as an enhancer of Wnt/beta-catenin signaling in melanoma. Chem Biol. 2010;17(11):1177-1182.
91. Chia NY, Chan YS, Feng B, et al. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature. 2010; 468(7321):316-320.
92. Jiang SQ, Paulus H. A high-throughput, homogeneous, fluorescence polarization assay for inhibitors of hedgehog protein autoprocessing. J Biomol Screen. 2010;15(9):1082-1087.
93. Lang DA, Hadley DM, Teasdale GM, Macpherson P, Teasdale E. Gadolinium-DTPA enhanced magnetic resonance imaging in human head injury. Acta Neurochir (Wien). 1990;51:293-295.
94. Thorne CA, Hanson AJ, Schneider J, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol. 2010;6(11):829-836.
95. Rubin LL. Stem cells and drug discovery: the beginning of a new era? Cell. 2008;132(4):549-552.
96. Jozefczuk J, Prigione A, Chavez L, Adjaye J. Comparative analysis of human embryonic stem cell and induced pluripotent stem cellderived hepatocyte-like cells reveals current drawbacks and possible strategies for improved differentiation. Stem Cells Dev. 2011;20(7): 1259-1275.
97. Park IH, Lerou PH, Zhao R, Huo H, Daley GQ. Generation of humaninduced pluripotent stem cells. Nat Protoc. 2008;3(7):1180-1186.
98. Kanemura Y. Development of cell-processing systems for human stem cells (neural stem cells, mesenchymal stem cells, and iPS cells) for regenerative medicine. Keio J Med. 2010;59(2):35-45.
99. Knorr DA, Kaufman DS. Pluripotent stem cell-derived natural killer cells for cancer therapy. Transl Res. 2010;156(3):147-154.
100. Schwarz SC, Schwarz J. Translation of stem cell therapy for neurological diseases. Transl Res. 2010;156(3):155-160.
101. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev. 2008;8(10): 755-768.